Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Ketones
Parkinson Disease, Lewy Body Dementia, Parkinson Disease Dementia
About this trial
This is an interventional treatment trial for Parkinson Disease focused on measuring ketone ester, ketosis, functional neuroimaging
Eligibility Criteria
Inclusion Criteria: Healthy control volunteers over 45 years of age People with Parkinson Disease over 45 years of age People with Parkinson's Disease Dementia or Lewy Body Dementia over 45 years of age Exclusion Criteria: Participants with contra-indications to MR imaging, including pacemakers or claustrophobia; Evidence of large vessel stroke or mass lesion on MRI Regular use of anti-cholinergic, benzodiazepines, high dose (>100mg QD) of quetiapine, or neuroleptic drugs History of significant GI disease Significant metabolic or uncontrolled medical comorbidity Poorly controlled diabetes Pregnancy or breast feeding Current excessive alcohol use Suicidal ideation
Sites / Locations
- Domino's FarmsRecruiting
- University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Parkinson Disease
Parkinson Disease Dementia/Lewy Body Dementia
Healthy Controls
Participants will take the ketone ester supplement for 30 days +/- 7 days. For days 1 through 7, participants will take 12.5g (25mL) of the ketone ester supplement (KetoneAid) TID, and on day 8, the dose will be increased to 25g (50mL) three times daily (TID) as tolerated. KE dose will be titrated down to a tolerated level if necessary.
Participants will take the ketone ester supplement for 30 days +/- 7 days. For days 1 through 7, participants will take 12.5g (25mL) of the ketone ester supplement (KetoneAid) TID, and on day 8, the dose will be increased to 25g (50mL) TID as tolerated. KE dose will be titrated down to a tolerated level if necessary.
Participants will take the ketone ester supplement for 30 days +/- 7 days. For days 1 through 7, participants will take 12.5g (25mL) of the ketone ester supplement (KetoneAid) TID, and on day 8, the dose will be increased to 25g (50mL) TID as tolerated. KE dose will be titrated down to a tolerated level if necessary.